Core Viewpoint - Bernstein Liebhard LLP is reminding investors of Vistagen Therapeutics, Inc. about a deadline related to a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - A class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, alleging violations of the Securities Exchange Act of 1934 [3]. - The lawsuit claims that the defendants made misrepresentations regarding the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the acute treatment of social anxiety disorder [4]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiff for the class must file papers by March 16, 2026, with the role involving directing the litigation on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [6]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an ...

LOS ANGELES, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vistagen Therapeutics, Inc., (“Vistagen” or the "Company") (NASDAQ: VTGN) investors of a class action on behalf of investors that bought securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). Vistagen investors have until March 16, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss the ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's clinical trial results [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Vistagen between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Vistagen and its executives made false statements regarding the likelihood of success in the PALISADE-3 clinical trial, which misled investors and caused them to purchase shares at inflated prices [5]. Group 2: Clinical Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study for fasedienol failed to meet its primary efficacy endpoint, leading to a significant stock price drop of over 81%, opening at $0.88 per share [6]. - The study did not demonstrate statistically significant improvement in anxiety reduction compared to placebo, which contradicted previous positive assertions made by the company [5][6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [8].

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant drop in stock price [3][4]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for social anxiety disorder [3]. - The company’s investigational drug, fasedienol, was under evaluation in the Phase 3 PALISADE-3 trial [3]. Group 2: Trial Results and Allegations - The PALISADE-3 trial did not show a statistically significant improvement on the primary endpoint, which was the change on the Subjective Units of Distress Scale [3]. - Defendants allegedly provided positive statements while concealing adverse facts about the trial results [3]. Group 3: Stock Price Impact - Following the announcement of the trial results on December 17, 2025, Vistagen's stock price plummeted from $4.36 per share to $0.86 per share, representing a decline of over 80% [3]. Group 4: Legal Proceedings - Shareholders who purchased shares during the class period from April 1, 2024, to December 16, 2025, are encouraged to register for the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is March 16, 2026 [4].

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/vistagen-therapeu ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026. SO WHAT: If you purchased Vistagen Therapeutics common stock du ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol, leading to inflated stock prices during the class period from April 1, 2024, to December 16, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen's management made positive assertions about the success of fasedienol based on prior clinical trial results, which misled investors [5]. - It is alleged that while promoting the drug's potential, the company concealed material adverse facts about the Phase 3 PALISADE-3 trial, resulting in shareholders purchasing stock at artificially inflated prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron D ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...